Skip to main content
main-content

Ophthalmology

Ophthalmology

17-01-2019 | Ophthalmology | News | Article

Statin use lowers diabetic retinopathy risk

Statin therapy may reduce the risk of diabetic retinopathy and the need for its associated invasive treatments in patients with type 2 diabetes and dyslipidaemia, population-based study findings indicate.

Source:

JAMA Ophthalmol 2019; doi:10.1001/jamaophthalmol.2018.6399

10-01-2019 | Ophthalmology | News | Article

Optical coherence tomography highlights retinal changes post-implantation

Researchers have used optical coherence tomography to reveal the development of a fibrosis-like hyper-reflective tissue at the interface between the electronic array and retina in patients who have undergone electronic retinal prosthesis implantation.

Source:

JAMA Ophthalmol 2019; doi:10.1001/jamaophthalmol.2018.6375
JAMA Ophthalmol 2019; doi:10.1001/jamaophthalmol.2018.6386

21-12-2018 | Ophthalmology | News | Article

Electronic health record-linked glaucoma medication reminders well-received

The majority of patients with glaucoma appear willing to sign up to receive automated medication reminders linked to their electronic health records, with most describing them as useful, US research shows.

Source:

JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.6066
JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.6074

13-12-2018 | Ophthalmology | News | Article

Predictors of poor outcome with anti-VEGF therapy identified for nAMD

Researchers from the Fight Retinal Blindness! study group have identified a number of variables that predict of sustained loss of visual acuity in patients with neovascular age-related macular degeneration.

Source:

Ophthalmol 2018; doi:10.1016/j.ophtha.2018.11.036

06-12-2018 | Ophthalmology | News | Article

SRF tolerant ranibizumab regimen does not negatively impact visual outcomes

Tolerating some subretinal fluid during a treat-and-extend ranibizumab protocol does not detrimentally affect visual acuity in patients with neovascular age-related macular degeneration, study findings indicate.

Source:

Ophthalmol 2018; doi:10.1016/j.ophtha.2018.11.025

29-11-2018 | Ophthalmology | News | Article

Treatment-related non-fibrotic scars do not negatively affect vision

Developing non-fibrotic scars during the first year of anti-vascular endothelial growth factor treatment does not have a detrimental effect on visual acuity during the following 4 years, US researchers report.

Source:

Ophthalmology 2018; doi:10.1016/j.ophtha.2018.11.020

22-11-2018 | Ophthalmology | News | Article

Fixed-combination BBFC improves 24-hour intraocular pressure after 4 weeks

Treatment with fixed-combination brinzolamide 1%/brimonidine 0.2% for 4 weeks significantly reduces 24-hour intraocular pressure in patients with open-angle glaucoma or ocular hypertension, US researchers report.

Source:

Ophthalmol 2018; doi:10.1016/j.ophtha.2018.10.040

15-11-2018 | Ophthalmology | News | Article

Current glaucoma staging systems underestimate disease severity

Current glaucoma staging systems based on 24-2 (or 30-2) visual fields underestimate disease severity and the presence of macular damage when compared with 10-2 visual fields and high-resolution macular imaging, US researchers report.

Source:

JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.5398

01-11-2018 | Ophthalmology | News | Article

Long-term mineralocorticoid receptor antagonists beneficial in chronic CSC

 The majority of patients with chronic non-resolving central serous chorioretinopathy will experience complete resolution following 2 years of treatment with a mineralocorticoid receptor antagonist, study findings indicate.

Source:

Br J Ophthalmol 2018; doi:10.1136/bjophthalmol-2018-312892

25-10-2018 | Ophthalmology | News | Article

Moderate agreement shown between ETDRS 7- and ultrawide-field imaging for DR

Agreement between Early Treatment Diabetic Retinopathy Study 7-field imaging and ultrawide-field imaging is moderate when assessing the severity of diabetic retinopathy in patients with type 1 or type 2 diabetes, US research shows.

Source:

JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.4982

18-10-2018 | Ophthalmology | News | Article

Deep learning classifier may aid diagnosis of early glaucoma

A deep learning classifier model developed to diagnose early glaucoma is significantly more accurate than other machine learning methods, Japanese researchers report.

Source:

Am J Ophthalmol 2018; doi:10.1016/j.ajo.2018.10.007

11-10-2018 | Ophthalmology | News | Article

Intralesional MA common in anti-VEGF treated nAMD

Intralesional macular atrophy is common in individuals with neovascular age-related macular degeneration undergoing treatment with vascular endothelial growth factor inhibitors, study findings indicate.

Source:

Ophthalmology 2018; doi:10.1016/j.ophtha.2018.07.013

04-10-2018 | Ophthalmology | News | Article

Intravitreal superior to periocular therapy for initial uveitic ME

Treatment with intravitreal triamcinolone acetonide or intravitreal dexamethasone implant results in greater improvements in uveitic macular oedema than treatment with periocular triamcinolone acetonide, US research shows.

Source:

Ophthalmology 2018; doi:10.1016/j.ophtha.2018.08.021

16-10-2017 | Oncology | News | Article

News in brief

‘Surrogate’ retinoblastoma biopsy feasible using aqueous humor

Tumor-specific DNA can be retrieved from the aqueous humor of patients with retinoblastoma, say US researchers, allowing genetic analysis in patients who do not have a biopsy sample available.

23-11-2016 | Oncology | News | Article

News in brief

Ocular side effects of MEK inhibitors documented

Mitogen-activated protein kinase inhibitors are associated with a wide range of ocular complications, highlighting the importance of ophthalmic monitoring.

17-06-2016 | Diabetes | News | Article

News in brief

Best diabetic macular oedema drugs ‘not cost-effective’

Resource utilisation data from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial show that the most efficacious drug for diabetic macular oedema, aflibercept, is not cost-effective relative to repackaged bevacizumab.

05-01-2016 | Neurology | News | Article

Editor's pick

Failure to accurately assess optic nerve drives IIH overdiagnosis

Researchers put overdiagnosis of idiopathic intracranial hypertension down to inaccurate ophthalmoscopic examination in headache patients and wrongly suspecting the condition in young obese women with headaches.

Source:

Neurology 2015; Advance online publication

image credits